Literature DB >> 7673423

Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor.

B Casslén1, J Nordengren, B Gustavsson, M Nilbert, L R Lund.   

Abstract

Progesterone stimulates differentiation and inhibits the growth of endometrial tissue. Also, progesterone reduces plasminogen activator (PA) activity, which implies reduced turnover of extracellular matrix proteins in the secretory phase. To elucidate the mechanism responsible for reduced PA activity, primary cultures of human endometrial stromal cells were stimulated with estradiol and progesterone. Conditioned media were assayed for urokinase-type and tissue-type PA (u-PA and t-PA, respectively), PA inhibitor-1 (PAI-1), and PA activity. Binding of [125I]u-PA and [125I]u-PA:PAI-1 complex to the u-PA receptor and clearance of these ligands were studied. The PA activity of conditioned medium decreased after stimulation with progesterone, and this was secondary to a decrease in u-PA, but not t-PA, and an increase in PAI-1. Northern blot analysis showed induction of PAI-1 messenger ribonucleic acid, whereas the content of u-PA messenger ribonucleic acid was not influenced. Furthermore, the number of free u-PA receptor-binding sites was increased by estradiol and progesterone. The stromal cells degraded complexed u-PA more efficiently than free u-PA, and degradation of both ligands was inhibited by colchicine, chloroquine, and methylamine. Degradation was increased after hormone treatment, and this was apparently due to increased ligand binding, because neither ligand affinity nor the relative rate of degradation was increased. Increased expression of u-PA receptor-binding sites was not regulated on the transcriptional level, but may result from posttranslational mechanisms, such as decreased turnover of the receptor. Activation of plasminogen by receptor bound u-PA initiates a cascade of proteolytic events in the extracellular matrix that is important during tissue proliferation. Our data suggest that differentiated endometrial stroma in the secretory phase regulates extracellular proteolysis by increased elimination of u-PA through increased release of PAI-1 and increased u-PA receptor density.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673423     DOI: 10.1210/jcem.80.9.7673423

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3.

Authors:  Donna C Sinclair; Alex Mastroyannis; Hugh S Taylor
Journal:  J Clin Endocrinol Metab       Date:  2010-11-17       Impact factor: 5.958

2.  A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus.

Authors:  Magali Ancelin; Hélène Buteau-Lozano; Geri Meduri; Mary Osborne-Pellegrin; Sylvie Sordello; Jean Plouët; Martine Perrot-Applanat
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

3.  The Plasminogen Activator System, Glucocorticoid, and Mineralocorticoid Receptors in the Primate Endometrium During Artificial Menstrual Cycles.

Authors:  Esra Demirel; Reem Sabouni; Neelima Chandra; Ov D Slayden; David F Archer
Journal:  Reprod Sci       Date:  2021-11-18       Impact factor: 3.060

4.  Upregulation of CFTR in patients with endometriosis and its involvement in NFκB-uPAR dependent cell migration.

Authors:  Wenqing Huang; Aihong Jin; Jieting Zhang; Chaoqun Wang; Lai Ling Tsang; Zhiming Cai; Xiaping Zhou; Hao Chen; Hsiao Chang Chan
Journal:  Oncotarget       Date:  2017-03-22

5.  SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway.

Authors:  Ye Song; Zhuo Li; Lei Li; Houming Zhou; Ting-Ting Zeng; Chuan Jin; Jin-Rong Lin; Sha Gao; Yan Li; Xin-Yuan Guan; Ying-Hui Zhu
Journal:  J Hepatocell Carcinoma       Date:  2021-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.